Pedro Eduardo Nascimento Silva Vasconcelos

Universidade Estadual de Campinas (UNICAMP)

Biochemistry, Genetics and Molecular BiologyMedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors”.

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors

JTO Clinical and Research Reports(2020)10.1016/j.jtocrr.2020.100051

N/A

0DataRank · unranked

81 citations

Carol Gergis, Hollis Viray, Andreas Varkaris, Masanori Fujii, Deepa Rangachari +5 more

Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations

JTO Clinical and Research Reports(2020)10.1016/j.jtocrr.2020.100105

N/A

0DataRank · unranked

23 citations

Ikei S. Kobayashi, Susumu Kobayashi, Daniel B. Costa, Pedro Eduardo Nascimento Silva Vasconcelos

Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutations

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.09.28.317560

N/A

0DataRank · unranked

20 citations

Ikei S. Kobayashi, Susumu Kobayashi, Daniel B. Costa, Pedro Eduardo Nascimento Silva Vasconcelos